Medidata Secures Top Honors in Everest Group’s Decentralized Clinical Trial Platforms PEAK Matrix® Assessment

NEW YORK -- Businesswire -- Medidata (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.medidata.com%2Fen%2F&esheet=53879943&newsitemid=20240110694798&lan=en-US&anchor=Medidata&index=1&md5=f2d573b2db328d38013e48d43cda4d12), a Dassault Systèmes company and leading provider of clinical trial solutions to the life sciences industry, has again been recognized as a Leader in Everest Group’s recently published “Decentralized Clinical Trials Platforms PEAK Matrix® Assessment 2023 (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.medidata.com%2Fen%2Feverest-decentralized-clinical-trial-platforms-peak-matrix-2023%2F&esheet=53879943&newsitemid=20240110694798&lan=en-US&anchor=Decentralized+Clinical+Trials+Platforms+PEAK+Matrix%26%23174%3B+Assessment+2023&index=2&md5=70a9810253f7fdc49d899d8891e5f221).” Medidata was the only provider to receive a “Star Performer” designation for the second consecutive year, reflecting its continued innovation and leadership.

The report evaluated the vision, capabilities, and market impact of 22 decentralized clinical trial (DCT) platform providers based on relevant customer case studies, revenue, key offerings, and their latest progress.

“Medidata’s unified platform harnesses DCT technology to optimize patient, site, and sponsor experiences, delivering more inclusive studies,” said Anthony Costello, chief executive officer, Medidata Patient Cloud, Medidata. “We’re honored to be recognized as a Leader by Everest Group in DCT platform providers, demonstrating our extensive experience and leadership in a rapidly evolving industry.”

In this year’s assessment, Medidata distinguished itself through substantial investments in next-generation and patient-centric DCT technologies within Medidata AI and Medidata Patient Cloud, such as the Medidata Diversity Program (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.medidata.com%2Fen%2F092023_amer_diversity-program-fact-sheet%2F&esheet=53879943&newsitemid=20240110694798&lan=en-US&anchor=Medidata+Diversity+Program&index=3&md5=378a050032ae65c1e8597d8119d11c24), the myMedidata application (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.medidata.com%2Fen%2Fclinical-trial-products%2Fpatient-centric-clinical-trials%2Fmymedidata%2F&esheet=53879943&newsitemid=20240110694798&lan=en-US&anchor=myMedidata+application&index=4&md5=4e97f1dfdeb7b580a52417349faf8ae3), and Medidata Rave Companion (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.medidata.com%2Fen%2Fclinical-trial-products%2Fclinical-data-management%2Frave-companion%2F&esheet=53879943&newsitemid=20240110694798&lan=en-US&anchor=Medidata+Rave+Companion&index=5&md5=a02452b9d97d6a4faa3f18726a51c2f5). As a Leader, Medidata was also recognized for its domain expertise and user experience for patients and sites, as well as its global capabilities to orchestrate DCTs.

“Medidata offers an end-to-end, comprehensive DCT platform, covering ePRO/eCOA, eConsent, televisits, patient recruitment, and engagement. With deep domain expertise, strategic partnerships, and industry experience, Medidata has achieved widespread adoption of its solutions,” said Nisarg Shah, practice director at Everest Group. “Its investments in building a unified experience for sites and patients have positioned Medidata as a Leader and a Star Performer in the Decentralized Clinical Trial Platforms PEAK Matrix Assessment 2023.”

Medidata’s platform has powered nearly 1,700 DCTs and over 1.1 million patients across disease areas, countries, languages, and clinical trial phases. With this technology, Medidata supports patient participation in the right trial at the right time, from anywhere and with easier, faster, and better results.​​

About Medidata Medidata is powering smarter treatments and healthier people through digital solutions to support clinical trials. With over 20 years of groundbreaking technological innovation across more than 30,000 trials and 9 million patients, Medidata offers industry-leading expertise, analytics-powered insights, and the largest patient-level historical clinical trial data set in the world. More than 1 million registered users across 2,100+ customers trust Medidata’s seamless, end-to-end platform to improve patient experiences, accelerate clinical breakthroughs, and bring therapies to market faster. The company is a wholly owned subsidiary of Dassault Systèmes (Euronext Paris: FR0014003TT8, DSY.PA), which with its 3DEXPERIENCE platform is positioned to lead the digital transformation of life sciences in the age of personalized medicine with the first end-to-end scientific and business platform, from research to commercialization. Medidata is headquartered in New York City and has been recognized as a Leader by Everest Group and IDC. Discover more at www.medidata.com and follow us @Medidata.

About Dassault Systèmes Dassault Systèmes, the 3DEXPERIENCE® Company, is a catalyst for human progress. We provide business and people with collaborative virtual environments to imagine sustainable innovations. By creating virtual twin experiences of the real world with our 3DEXPERIENCE platform and applications, our customers can redefine the creation, production and life-cycle-management processes of their offer and thus have a meaningful impact to make the world more sustainable. The beauty of the Experience Economy is that it is a human-centered economy for the benefit of all -consumers, patients, and citizens. Dassault Systèmes brings value to more than 300,000 customers of all sizes, in all industries, in more than 150 countries. For more information, visit www.3ds.com

© Dassault Systèmes. All rights reserved. 3DEXPERIENCE, the 3DS logo, the Compass icon, IFWE, 3DEXCITE, 3DVIA, BIOVIA, CATIA, CENTRIC PLM, DELMIA, ENOVIA, GEOVIA, MEDIDATA, NETVIBES, OUTSCALE, SIMULIA and SOLIDWORKS are commercial trademarks or registered trademarks of Dassault Systèmes, a European company (Societas Europaea) incorporated under French law, and registered with the Versailles trade and companies registry under number 322 306 440, or its subsidiaries in the United States and/or other countries.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240110694798/en/

이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.

출처:Medidata

보도자료 통신사 뉴스와이어(www.newswire.co.kr) 배포